The Best Dividend King to Buy With $150
Shares of Abbott Laboratories (NYSE: ABT) recently plunged after the company announced its fourth-quarter results. Over the trailing 12 months, the stock is down 16%. Some might choose to stay away from Abbott given some recent challenges. However, Abbott's stock still remains attractive, especially for dividend-seeking investors. Here is why.
Abbott Laboratories' fourth-quarter top-line growth came up short of expectations. The company's sales were $11.5 billion, up 4.4% compared to the year-ago period. Two of the company's business segments, nutrition and diagnostics, moved in the wrong direction. And to make matters worse, the company's guidance for its fiscal 2026 was not strong either. It's not that surprising, then, that Abbott's shares fell sharply on the heels of its earnings release.
Image source: Getty Images.
Source Fool.com
Abbott Laboratories Stock
The stock is an absolute favorite of our community with 65 Buy predictions and no Sell predictions.
With a target price of 117 € there is a hugely positive potential of 59.49% for Abbott Laboratories compared to the current price of 73.36 €.
